evacetrapib + gemfibrozil

Evacetrapib + gemfibrozil refers to the *co-administration* of two distinct drugs, each with different mechanisms of action: - **Evacetrapib** is a small molecule cholesteryl ester transfer protein (CETP) inhibitor, developed primarily for the reduction of major adverse cardiovascular events through raising HDL-cholesterol and lowering LDL-cholesterol. - **Gemfibrozil** is a fibric acid derivative (fibrate), a peroxisome proliferator-activated receptor alpha (PPARα) agonist, used mostly to reduce triglycerides and increase HDL cholesterol. The combination has been studied in phase 1 clinical trials in healthy subjects to assess pharmacokinetic interactions and safety. Results indicate that co-administration does not meaningfully alter the pharmacokinetics or safety profile of either drug. Both drugs are administered orally[1][3][4].